TICKERNERD
Menu
AGENAGENHealthcare · Biotechnology

AGEN Stock Forecast: Agenus, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$7.54
−0.40% on the day

The 3 Wall Street analysts covering Agenus, Inc. hold a median 12-month price target of $25 — +231.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$338.3M
Ticker Nerd rank
87 / 100
Median analyst target
$25
Analysts covering
3
Revenue$34.5M+34.4% y/y
Operating income$11.3M
Net income−$567K
Free cash flow−$31.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.5%
1M
+1.5%
YTD
+140.1%
1Y
+80.8%
From 52W high
−24.1%
From 52W low
+172.2%
$2.77
$9.93
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Agenus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
96
Quality
95
Momentum
83
Issuance
69
Size
59
Accruals
43
Revisions
26
Volatility
25

Growth (99): Sales and profits are climbing, and climbing faster than before.

Volatility (25): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00Jan 26Apr 26Jul 26Oct 26AGENHigh $40Median $25Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $14Median $25High $40

The green dot is the last close — the median target sits +231.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
5 Oct 2026Chardan CapitalMaintainsBuy$40
28 Sept 2026Rodman & RenshawInitiatesBuy$19
18 Sept 2026Chardan CapitalInitiatesBuy$40
18 Sept 2026Chardan CapitalInitiatesBuy—
11 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $25
11 Aug 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$8.00 → $14
30 July 2026B. Riley SecuritiesMaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy$23 → $30
13 July 2026HC Wainwright & Co.MaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
4 June 2025BairdMaintainsNeutral—
4 June 2025HC Wainwright & Co.UpgradeBuy—
13 May 2025BairdMaintainsNeutral—
13 May 2025HC Wainwright & Co.ReiteratesNeutral—
30 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
18 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025BairdMaintainsNeutral—
12 Mar 2025HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Agenus, Inc. returned +80.8% against +16.2% for the S&P 500, dividends included.

AGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26AGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+100.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Agenus, Inc. (AGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.0×

Cheaper than 68% of US stocks

Price / sales
2.5×

Cheaper than 45% of US stocks

Price / book
−1.5×

Cheaper than 95% of US stocks

EV / EBITDA
8.7×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
34.4%

Higher than 80% of US stocks

Earnings growth (YoY)
34.4%

Higher than 68% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
32.7%

Higher than 88% of US stocks

Net margin
69.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
0.0%

Higher than 44% of US stocks

Return on assets
12.5%

Higher than 95% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Agenus, Inc. (AGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Agenus, Inc. has a market value of $338.3M and an enterprise value of $352.4M.

  • Revenue in the twelve months to 30 June 2026: $132.7M. The latest quarter grew 34.4% year on year.

  • Net income over the same four quarters: $91.9M, a 69.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$98.5M.

  • Agenus, Inc. spent $54K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 44.8M.

  • Trailing P/E: 3.0×; forward P/E: −68.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Agenus, Inc. employs 81 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

AGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AGENAgenus, Inc.$338.3M
87
TTRXTurn Therapeutics, Inc.$335.4M
19
OBIOOrchestra Biomed Holdings, Inc.$335.3M
43
RLMDRelmada Therapeutics, Inc.$332.5M
64
OCGNOcugen, Inc.$330.9M
21
ARTVArtiva Biotherapeutics, Inc.$330.4M
33
CCCCC4 Therapeutics, Inc.$350.6M
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Agenus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AGEN news & analysis

Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Business Wire · 8 Oct 2026positive

Agenus announced that Armenia’s Ministry of Health granted marketing authorizations for Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination for adults with previously treated MSS metastatic colorectal cancer without active liver metastases.

Why it matters — The authorizations mark the first marketing approvals for Agenus’ BOT+BAL combination in this patient population.

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Business Wire · 3 Oct 2026positive

Agenus announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial, reporting an estimated 48% three-year survival with the botensilimab (BOT) and balstilimab (BAL) combination in recurrent ovarian cancer, presented at IGCS 2026. The results include outcomes broken down by sensitivity to platinum-based chemotherapy.

Why it matters — The three-year survival data from the botensilimab and balstilimab combination provides a key durability signal for Agenus' lead immuno-oncology candidates in a difficult-to-treat recurrent ovarian cancer setting.

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Business Wire · 2 Oct 2026positive

Agenus announced that two posters on botensilimab (BOT) in combination with balstilimab (BAL), and translational research on agenT-797 in colorectal cancer, have been accepted for presentation at the SITC 2026 Annual Meeting in Phoenix, Arizona, November 4-8, 2026. The clinical poster will review long-term survival data.

Why it matters — AGEN watchers would care because presentations of long-term survival data and translational research at a major immunotherapy conference could provide a public update on the clinical progress of Agenus's lead combination therapies.

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Seeking Alpha · 11 Sept 2026neutral

The item is a transcript of a shareholder/analyst call for Agenus Inc. (AGEN), published by Seeking Alpha. No substantive details beyond the transcript's availability are provided in the excerpt.

Why it matters — A transcript of an Agenus shareholder/analyst call gives investors a record of management's commentary and answers to analyst questions.

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Business Wire · 10 Sept 2026neutral

Agenus announced that a poster on botensilimab combined with balstilimab has been accepted for presentation at the International Gynecologic Cancer Society Annual Global Meeting, October 1-3, 2026, in Montreal. The presentation will feature results from its recurrent ovarian cancer study.

Why it matters — The presentation is an opportunity for AGEN watchers to see three-year overall survival data on the BOT+BAL combination in recurrent ovarian cancer, a key readout for the company's pipeline.

FAQ

Frequently asked questions about AGEN stock

What is the AGEN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Agenus, Inc. have a median 12-month price target of $25, with estimates ranging from $14 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGEN stock a buy right now?

Of the 3 analysts covering Agenus, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agenus, Inc. 87 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGEN?

As at 8 Oct 2026, Agenus, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will AGEN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +231.6% from the last close, and Ticker Nerd's factor model ranks Agenus, Inc. 87 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGEN stock forecast for 2030?

No analyst covering Agenus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $40 over the next 12 months.

How has AGEN stock performed over the past year?

Agenus, Inc. returned +80.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agenus, Inc. do?

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer.

What is the latest news on AGEN?

The most recent item we track (Business Wire, 8 Oct 2026): "Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer". Agenus announced that Armenia’s Ministry of Health granted marketing authorizations for Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination for adults with previously treated MSS metastatic colorectal cancer without active liver metastases.

Company

About Agenus, Inc.

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes vaccine adjuvants and cell therapy programs, supported by proprietary discovery platforms and in-house manufacturing and clinical development capabilities. The company’s lead programs center on botensilimab and balstilimab, which are being advanced in multiple solid-tumor settings, including colorectal cancer and other difficult-to-treat cancers. Agenus also works through subsidiaries and partners to support adoptive cell therapies and adjuvant technologies, giving it a broad role across the immunotherapy value chain. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. remains a specialist developer in the cancer immunotherapy market.

CEO Dr. Garo H. Armen Ph.D. · 81 employees · United States · https://www.agenusbio.com